Esperion Announces Submission Of Supplemental New Drug Applications To U.S. FDA For NEXLETOL Tablet And NEXLIZET Tablet
Portfolio Pulse from Benzinga Newsdesk
Esperion has submitted supplemental New Drug Applications (sNDAs) to the U.S. FDA for NEXLETOL and NEXLIZET tablets, aiming to expand their indications.

June 01, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Esperion's submission of sNDAs for NEXLETOL and NEXLIZET tablets to the U.S. FDA may lead to expanded indications and increased market potential.
Esperion's submission of sNDAs for NEXLETOL and NEXLIZET tablets to the U.S. FDA indicates the company's efforts to expand the indications for these drugs. If approved, this could lead to increased market potential and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100